BPC-157's reputation as a tissue repair peptide rests on a growing body of preclinical research showing accelerated healing across multiple tissue types. Understanding the molecular mechanisms behind these effects — particularly VEGF receptor upregulation and FAK-paxillin signalling — helps explain why BPC-157 has become one of the most studied peptides in musculoskeletal research.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. Its amino acid sequence — GEPPPGKPADDAGLV — was isolated and synthesised for research purposes, and has demonstrated remarkable stability compared to many other peptides, being resistant to degradation in both gastric acid and plasma.
The compound is notable for its pleiotropic effects — it appears to act through multiple pathways simultaneously, which may explain why its healing effects are observed across such diverse tissue types including tendon, ligament, bone, muscle, skin, and gastrointestinal mucosa.
One of the primary mechanisms through which BPC-157 promotes tissue repair is upregulation of VEGF (vascular endothelial growth factor) and its receptors. VEGF is the master regulator of angiogenesis — the formation of new blood vessels — which is essential for tissue repair. Without adequate vascularisation, healing tissue cannot receive sufficient oxygen and nutrients, and repair processes stall.
Preclinical studies using tendon and ligament repair models have shown that BPC-157 administration significantly increases VEGF expression at the site of injury within 24-48 hours. This is followed by measurable increases in capillary density in the healing tissue, which correlates with faster functional recovery in the animal models studied.
Equally important to BPC-157's tissue repair effects is its activation of the FAK (Focal Adhesion Kinase) and paxillin signalling pathway. FAK is a critical mediator of cell adhesion, migration, and proliferation — all essential processes in wound healing and tissue repair. When FAK is activated, it phosphorylates paxillin, a scaffolding protein that coordinates cytoskeletal reorganisation and cell movement.
In the context of tendon repair, FAK-paxillin activation promotes the migration of tenocytes (tendon cells) to the injury site and stimulates collagen synthesis. Research has shown that BPC-157 activates this pathway in both in vitro cell culture models and in vivo tissue repair studies, with measurable increases in FAK phosphorylation occurring within hours of administration.
BPC-157 also modulates the nitric oxide (NO) system, which plays a complex role in tissue repair. While excessive NO production can be inflammatory, appropriate NO signalling is essential for vasodilation, which increases blood flow to injured tissue, and for activation of growth factor receptors. Studies suggest BPC-157 fine-tunes NO production rather than simply increasing or decreasing it, which may explain its ability to reduce inflammation while simultaneously promoting healing.
Beyond musculoskeletal repair, BPC-157's gastric protective effects have been extensively studied. The compound appears to accelerate healing of gastric ulcers through PGE2 synthesis modulation and by directly stimulating proliferation of gastric mucosal cells. Research in colitis models has shown significant reduction in inflammatory markers and accelerated mucosal recovery, making BPC-157 of particular interest in gastrointestinal research.
Most BPC-157 research has been conducted in rodent models, and translational applicability requires further investigation. When using BPC-157 in research protocols, reconstitution in bacteriostatic water or sterile saline is recommended, with storage at -20°C maintaining integrity for up to 36 months in lyophilised form. Our supplied BPC-157 achieves 99.5% purity by HPLC with full mass spec verification.